Nishitha Reddy

10.0k total citations · 1 hit paper
116 papers, 2.3k citations indexed

About

Nishitha Reddy is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Nishitha Reddy has authored 116 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Pathology and Forensic Medicine, 53 papers in Genetics and 41 papers in Oncology. Recurrent topics in Nishitha Reddy's work include Lymphoma Diagnosis and Treatment (77 papers), Chronic Lymphocytic Leukemia Research (51 papers) and Viral-associated cancers and disorders (18 papers). Nishitha Reddy is often cited by papers focused on Lymphoma Diagnosis and Treatment (77 papers), Chronic Lymphocytic Leukemia Research (51 papers) and Viral-associated cancers and disorders (18 papers). Nishitha Reddy collaborates with scholars based in United States, United Kingdom and Italy. Nishitha Reddy's co-authors include Francisco J. Hernandez‐Ilizaliturri, Myron S. Czuczman, Bipin N. Savani, Jennifer R. Brown, Joy Knight, Mark S. Roth, Beata Holkova, George Deeb, Paul K. Wallace and John C. Byrd and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

Nishitha Reddy

107 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

2019 307 citations Jennifer R. Brown, Susan O’Brien et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nishitha Reddy United States	21	1.4k	1.0k	1.0k	534	511	116	2.3k
Stephen Opat Australia	25	1.7k 1.2×	1.4k 1.3×	980 1.0×	562 1.1×	570 1.1×	158	2.7k
Marı́a Dolores Caballero Spain	32	1.4k 0.9×	586 0.6×	1.2k 1.2×	657 1.2×	1.1k 2.2×	74	2.8k
Jonathon B. Cohen United States	23	1.7k 1.2×	725 0.7×	1.6k 1.6×	579 1.1×	184 0.4×	131	2.4k
Samantha Jaglowski United States	24	1.2k 0.8×	1.5k 1.4×	940 0.9×	896 1.7×	992 1.9×	152	2.9k
Ahmed Hamdy United States	18	1.6k 1.1×	1.9k 1.9×	527 0.5×	732 1.4×	668 1.3×	60	2.5k
Stefano Molica Italy	31	1.4k 1.0×	1.9k 1.8×	726 0.7×	980 1.8×	671 1.3×	170	3.0k
Rudolf Schlag Germany	16	669 0.5×	808 0.8×	1.0k 1.0×	310 0.6×	973 1.9×	60	2.3k
Hyeon‐Seok Eom South Korea	24	679 0.5×	301 0.3×	864 0.9×	423 0.8×	530 1.0×	133	1.7k
H Tilly France	16	1.3k 0.9×	674 0.7×	856 0.8×	224 0.4×	460 0.9×	44	2.0k
G. Lepeu France	10	1.2k 0.9×	661 0.6×	775 0.8×	275 0.5×	245 0.5×	27	1.7k

Countries citing papers authored by Nishitha Reddy

Since Specialization

Citations

This map shows the geographic impact of Nishitha Reddy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nishitha Reddy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nishitha Reddy more than expected).

Fields of papers citing papers by Nishitha Reddy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nishitha Reddy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nishitha Reddy. The network helps show where Nishitha Reddy may publish in the future.

Co-authorship network of co-authors of Nishitha Reddy

This figure shows the co-authorship network connecting the top 25 collaborators of Nishitha Reddy. A scholar is included among the top collaborators of Nishitha Reddy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nishitha Reddy. Nishitha Reddy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Armand, Philippe, Seung‐Tae Lee, Wojciech Jurczak, et al.. (2025). WaveLINE-003: Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/refractory diffuse large B-cell lymphoma.. Journal of Clinical Oncology. 43(16_suppl). 7005–7005. 1 indexed citations

Mitra, Susweta Das, et al.. (2025). Hydrogel integrating CBEO-CINcocktail (Cinnamomum pauciflorum Nees bark oil enriched with cinnamaldehyde) loaded nanosponges exhibited potent antibacterial activity against carbapenem resistant bacterial pathogens - in vitro and in vivo evaluation. Industrial Crops and Products. 225. 120503–120503. 1 indexed citations

Advani, Ranjana H., Abraham Avigdor, David Lavie, et al.. (2023). Efficacy and Safety of Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study. Blood. 142(Supplement 1). 3068–3068. 1 indexed citations

Epperla, Narendranath, Qiuhong Zhao, Tamara K. Moyo, et al.. (2023). Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis. Blood Advances. 8(3). 549–552.

Suvannasankha, Attaya, Nizar J. Bahlis, Katja Weisel, et al.. (2022). P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY. HemaSphere. 6. 830–831. 3 indexed citations

Sethi, Tarsheen & Nishitha Reddy. (2018). Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies. Leukemia & lymphoma. 60(1). 6–18. 5 indexed citations

Reddy, Nishitha & Catherine Thiéblemont. (2017). Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective. Annals of Oncology. 28(11). 2680–2690. 12 indexed citations

Reddy, Nishitha. (2017). Management of Patients With Histologic Transformation. Clinical Lymphoma Myeloma & Leukemia. 17. S100–S104. 1 indexed citations

Bradshaw, Michael, Siddharama Pawate, Karen C. Bloch, Paul L. Moots, & Nishitha Reddy. (2016). Clinical Reasoning: A 52-year-old man with diplopia and ataxia. Neurology. 87(13). e140–3. 3 indexed citations

10.

Li, Shaoying, Vivian Weiß, Xuan J. Wang, et al.. (2015). High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis. The American Journal of Surgical Pathology. 40(2). 253–261. 37 indexed citations

11.

Wang, Xuan J., Adam C. Seegmiller, Nishitha Reddy, & Shaoying Li. (2015). CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B‐cell lymphoma. European Journal Of Haematology. 97(1). 39–47. 15 indexed citations

12.

Barr, Paul M., Jennifer R. Brown, Peter Hillmen, et al.. (2015). Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 33(15_suppl). 7012–7012. 6 indexed citations

13.

Iams, Wade T. & Nishitha Reddy. (2014). Consolidative autologous hematopoietic stem-cell transplantation in first remission for non-Hodgkin lymphoma: current indications and future perspective. Therapeutic Advances in Hematology. 5(5). 153–167. 10 indexed citations

14.

Reddy, Nishitha, et al.. (2013). Immune surveillance and lymphoid malignancy in immunocompromised host.. PubMed Central. 2 indexed citations

15.

Chinratanalab, Wichai, Nishitha Reddy, John P. Greer, et al.. (2012). Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies. Experimental Hematology. 40(6). 431–435. 3 indexed citations

16.

Reddy, Nishitha, Olalekan O. Oluwole, John P. Greer, et al.. (2012). Superior Long-Term Outcome of Patients With Early Transformation of Non-Hodgkin Lymphoma Undergoing Stem Cell Transplantation. Clinical Lymphoma Myeloma & Leukemia. 12(6). 406–411. 15 indexed citations

17.

Reddy, Nishitha & Bipin N. Savani. (2011). Primary central nervous system lymphoma: implication of high-dose chemotherapy followed by auto-SCT. Bone Marrow Transplantation. 47(10). 1265–1268. 2 indexed citations

18.

Head, David, et al.. (2011). High prevalence of obesity in acute promyelocytic leukemia (APL): implications for differentiating agents in APL and metabolic syndrome. Therapeutic Advances in Hematology. 2(3). 141–145. 20 indexed citations

19.

Reddy, Nishitha & M. S. Czuczman. (2010). Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies. Annals of Oncology. 21(9). 1756–1764. 35 indexed citations

20.

Reddy, Nishitha, Katayoun Rezvani, A. John Barrett, & Bipin N. Savani. (2010). Strategies to Prevent EBV Reactivation and Posttransplant Lymphoproliferative Disorders (PTLD) after Allogeneic Stem Cell Transplantation in High-Risk Patients. Biology of Blood and Marrow Transplantation. 17(5). 591–597. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact